Thymosin Alpha-1 Storage, Stability & Shelf Life: A Clinical Reference

HealthRX.com

No US label sets a storage temperature for thymosin alpha-1

Print or save as PDF

Key numbers

  • 1.6 mgDose of Zadaxin, the finished injection FDA names, authorized in some countries outside the USSource: fda.gov, as cited Nov 7, 2026
  • 4 weeksLength of the first Italian-label course, given twice weekly from the first vaccinationSource: fda.gov, as cited Nov 7, 2026
  • 1.8 to 2.6 hoursHalf-life of thymosin alpha-1 in healthy volunteers after subcutaneous injectionSource: fda.gov, as cited Nov 7, 2026

See the public record for Thymalfasin

  • US approval / Not FDA-approved; orphan designations are not approvals [1]
  • Finished product named by FDA / Zadaxin 1.6 mg injection, authorized outside the US [1]
  • Storage temperature / No US label sets one
  • Reconstituted stability / No US label sets one
  • Route and schedule (Italian label) / 1.6 mg subcutaneously or intramuscularly twice weekly [1]
  • Half-life / about 1.8 to 2.6 hours [1]

Does thymosin alpha-1 have a labeled storage temperature?

Thymosin alpha-1 has no FDA approval, so there is no US label to set a storage temperature, expiry or beyond-use date [1]. FDA identifies Zadaxin as a finished 1.6 mg injection authorized in some countries outside the US, including Italy, India and Hong Kong [1]. Zadaxin is not interchangeable with bulk Ta1 powder [1]. The Italian label, as FDA summarized it, gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 [1]. It says not for children and contraindicated in pregnancy and breastfeeding, with caution in allergies, autoimmune disease and other immune-modulating drugs [1].

Questions worth asking

Choose the questions you want to keep

What the published data on this peptide cover

The clinical literature describes what Ta1 does in the body, not how it behaves on a shelf. It is thought to modulate the immune system by augmenting T-cell function [2]. After subcutaneous injection in healthy volunteers, peak levels occur at about 0.7 to 2 hours and the half-life is about 1.8 to 2.6 hours, with no accumulation after daily dosing for five days [1]. A 2001 pharmacy review gives a serum half-life of about 2 hours [2]. General protein-stability reviews describe freezing and drying stresses in lyophilization and instability in solution and the dried state [3][4]; they are general reviews of protein drugs, not thymosin alpha-1 studies.

FDA's posted concerns about the bulk substance

FDA's page on bulk substances that may raise significant safety risks when compounded lists thymosin alpha-1 in the "nominated but withdrawn" table [5]. FDA's stated concerns remain posted: significant risk of immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information it called inadequate to understand the extent of any safety issues [5].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, does thymosin alpha-1 have a US-labeled storage temperature?

Question 1 of 5

Score: 0 right, 0 of 5 answered

What temperature should thymosin alpha-1 be stored at?
No US label sets a temperature because the drug is not FDA-approved [1].
How long does reconstituted thymosin alpha-1 last?
No US label gives a reconstituted beyond-use period, because thymosin alpha-1 is not FDA-approved [1].
Can thymosin alpha-1 be frozen?
No US label addresses freezing thymosin alpha-1, because none exists [1]. General protein reviews note that freezing and drying are stresses of lyophilization and that dried proteins may still lose stability during long-term storage [4].
Is Zadaxin the same as thymosin alpha-1?
Thymalfasin is the synthetic version of the 28-amino-acid peptide, and Zadaxin is the brand of the finished 1.6 mg injection sold outside the US [1]. Zadaxin is not interchangeable with bulk Ta1 powder, and neither is an FDA-approved product [1].
Show all 5 referencesHide references
  1. U.S. Food and Drug Administration.
  2. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
  3. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75.
  4. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60.
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
Evidence overview for Thymosin Alpha-1 Storage, Stability & Shelf Life: A Clinical Reference